The DOI matches its Crossref record; 325 of the 325 references it cites were found in a registry or an index.
Clinical Translation of Nanomedicine
Open accessAbstract
1. Introduction Nanomedicine, the application of nanotechnology to health and medicine, is a relatively new area of interdisciplinary science. The field involves a wide range of scientific disciplines, including physics, chemistry, engineering, biology, and medical science. The term nanomedicine can be traced back to the late 1990s and first appeared in research publications in the year 2000.1 Despite the wide adoption of the term nanomedicine, its definition varies among experts in this area.2 Some define nanomedicine broadly as any science that involves matters that are nanoscale. For example, the European Science Foundation in 2004 defined nanomedicine as “the science and technology of diagnosing, treating, and preventing disease and traumatic injury, of relieving pain, and of preserving and improving human health, using molecular tools and molecular knowledge of the human body”.2 While such a broad definition is all encompassing, it can be confusing. For example, such a definition would include traditional scientific fields such as molecular biology as part of nanomedicine, because molecules such as nucleic acids and proteins are also nanoscale materials. However, scientists have been studying these molecules decades before the term nanomedicine was even coined, and their research generally does not take advantage of unique properties that only exist for nanomaterials. A narrower definition of nanomedcine is the application of nanoscale material in medicine that takes advantage of the nanomaterial's unique properties.1 This Review will adopt this narrower definition in our discussion of the clinical translation of nanomedicine. Nanomedicine has made a rapid and broad impact on healthcare. Despite being only several decades old, research in nanomedicine has already led to the development of a wide range of products including therapeutics, diagnostic imaging agents, in vitro diagnostics, and medical devices. There are more than 200 nanomedicine products that have been either approved or are under clinical investigation.3 On the other hand, successful clinical translation is a challenging process. It requires extensive preclinical research, carefully selected clinical indication, proper design of clinical trials, and the successful completion of these trials. Mistakes in clinical translation can be unforgiving. Unlike preclinical research where there are many if not unlimited chances of generating a successful study, a single failed clinical trial can doom a drug's translation. Hay et al. recently showed that the eventual success rate of approval for therapeutics entering phase I trial is only about 10%.4 Because of this sobering statistic, it is important for translational researchers to fully understand the clinical translation process and to develop a successful translation strategy in the early stages of research. As compared to diagnostics and devices, clinical translation of therapeutics is arguably the most challenging. The typical clinical translation path for a new drug starts with investigators generating robust preclinical data to demonstrate the safety and efficacy of the new drug to enable an investigational new drug (IND) application with the Food and Drug Administration (FDA).5 Once the FDA has approved the IND, the therapeutic will be evaluated in a first-in-human or a phase I clinical trial. The goal of such a study is to determine the safety profile and pharmacology of the drug. It will result in a dose and schedule for further clinical investigation, or the recommended phase 2 dose (RP2D). The typical phase I trial design used a “3 + 3” cohort expansion design.6 This design assumes toxicity increases with dose, and it aims to determine the dose level that has less than 1/3 chance of a dose-limiting toxicity (DLT).7 In general, such a trial starts with a low drug dose. If none of the three patients receiving this dose experiences a DLT, another three patients will be treated at the next higher dose level. If one of the three patients experiences a DLT, then three more patients will be treated at the same dose level. Dose escalation continues until two patients among a cohort of three to six patients experience DLT. The RP2D is the dose level just below this level. Dose escalation typically follows a modified Fibonacci sequence where dose increments decrease as the tested dose increases. Other types of phase I designs include the accelerated titration designs, Bayesian models-based designs, and many others.7 Each design has advantages and disadvantages, and investigators have to choose the design that best fits the therapeutic. The goal of a phase II clinical trial is to examine the effectiveness of a drug or treatment. Secondarily, it will acquire more data on the toxicity and tolerability of the therapeutic. Therapeutics will progress to phase III clinical investigation only if they can demonstrate efficacy in phase II. The designs of phase II trials are either single-arm trials or randomized trials.8 Single-arm trials are cheaper, require fewer patients, and are typically easier to accrue. However, the outcome is less reliable as there is no comparison/control arm, and data are more susceptible to bias. Data from randomized phase II trials are more predictive of phase III results. However, it requires more patients and can be more difficult to accrue. Randomized phase II trials do not replace phase III investigations. Although they are randomized, patients are generally stratified on the basis of very few variables, such as age, sex, and disease status in phase II trials to keep the accrual goal low. Randomized phase III trials stratify patients on the basis of a large number of variables, which leads to less bias and more robust data. Because of the stratifications, the sample size required for phase III investigation is much higher than that of randomized phase II trials. The goal of randomized phase III trials is to demonstrate that the investigational treatment is more effective than the “gold standard” treatment. In general, phase III data are required for FDA approval. However, in select cases where there are robust data and unmet clinical needs, conditional approval can be granted on the basis of phase II data or interim phase III data. The FDA has a range of programs to speed up the approval process, including accelerated approvals and the recent “break through therapy” designation.9 There is a “short-cut” to FDA approval for agents that are based on already approved drugs. This pathway is called the 505(b)(2) pathway. The process of timeline for 505(b)(2) is much more abbreviated when compared to a typical approval process. For nanomedicine, this pathway will typically require that the exact nanoparticle platform is already approved with another agent and the drug being delivered by the nanoparticle is also approved. Past examples of this include the approval of liposomal bupivacaine with the DepoFoam liposome platform. The FDA was granted the authority to regulate medical devices in 1976.10 The approval process for medical devices is very different from that of drugs. First, for devices that predate May 28, 1976, these devices can remain on the market without needing approval. For the devices entering the market after that date, they are classified into different classes (I, II, and III) on the basis of their risks (Table 1).10 Class I devices are of low risk and are generally exempt from premarket notification (referred to as 510(k)) and may even be exempt from compliance with the good manufacturing practice requirement. Class II devices typically will require 510(k) submission before marketing. Class III devices are subject to the most stringent regulatory controls. Their approval will require a premarket approval (PMA) application. The 510(k) pathway is for devices that can be compared to existing, legally marketed “predicate” devices. The new device needs to be shown to be at least as safe and as effective as the “predicate” device. For devices that do not have a “predicate” device with which to compare, they are classified as class III and will need PMA. PMA needs to include scientific evidence that the device is safe and effective for its intended use. Unlike therapeutics where approvals generally require large randomized studies, scientific evidence for devices can include randomized controlled trials, single-arm studies, well-documented case series, and reports of significant human experience. For new devices that pose significant potential risks, an investigational device exemption (IDE) application is required prior to clinical investigation. Overall, the approval process is much simpler for devices than for therapeutics. Table 1 Summary of the FDA Device Regulation Processa In this Review, we will examine preclinical evidence, chosen clinical path to translation, and clinical data of clinically approved nanomedicine products. We will also discuss the clinical data on nanomedicines that are under clinical investigation or failed clinical translation. Each of these clinical nanomedicine products has a unique clinical translation story. By examining this body of evidence, we aim to formulate important concepts that are keys to nanomedicine's clinical translation and to identify challenges. Such concepts will facilitate the translation of future nanomedicine products.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Laurent, S., Forge, D., Port, M., Roch, A., Robic, C., Vander Elst, L., & Muller, R. N. (2008) · Chemical Reviews · doi:10.1021/cr068445e · Cited by 6,852
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00738a045 · Cited by 4,073
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Plasmonic photothermal therapy (PPTT) using gold nanoparticles
Huang, X., Jain, P. K., El-Sayed, I. H., & El-Sayed, M. A. (2008) · Lasers in Medical Science · doi:10.1007/s10103-007-0470-x · Cited by 2,376
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Reddy, L. H., Arias, J. L., Nicolas, J., & Couvreur, P. (2012) · Chemical Reviews · doi:10.1021/cr300068p · Cited by 2,010
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer
Harisinghani, M. G., Barentsz, J., Hahn, P. F., Deserno, W. M., Tabatabaei, S., van de Kaa, C. H., de la Rosette, J., & Weissleder, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022749 · Cited by 1,971
Polymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1958 · Cited by 1,962
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,655
The use of gold nanoparticles to enhance radiotherapy in mice
Hainfeld, J. F., Slatkin, D. N., & Smilowitz, H. M. (2004) · Physics in Medicine and Biology · doi:10.1088/0031-9155/49/18/n03 · Cited by 1,638
The emerging nanomedicine landscape
Wagner, V., Dullaart, A., Bock, A.-K., & Zweck, A. (2006) · Nature Biotechnology · doi:10.1038/nbt1006-1211 · Cited by 1,630
Maier-Hauff, K., Ulrich, F., Nestler, D., Niehoff, H., Wust, P., Thiesen, B., Orawa, H., Budach, V., & Jordan, A. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0389-0 · Cited by 1,429
Gabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
ELSAYED, I., HUANG, X., & ELSAYED, M. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.07.035 · Cited by 1,354
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211
Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery
Paciotti, G. F., Myer, L., Weinreich, D., Goia, D., Pavel, N., McLaughlin, R. E., & Tamarkin, L. (2004) · Drug Delivery · doi:10.1080/10717540490433895 · Cited by 1,185
Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1634 · Cited by 1,175
Hypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
Hrkach, J., Von Hoff, D., Ali, M. M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003651 · Cited by 1,147
Kelly, K., Crowley, J., Bunn, P. A., Presant, C. A., Grevstad, P. K., Moinpour, C. M., Ramsey, S. D., Wozniak, A. J., Weiss, G. R., Moore, D. F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3210 · Cited by 1,123
Taxol: A Novel Investigational Antimicrotubule Agent
Rowinsky, E. K., Cazenave, L. A., & Donehower, R. C. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.15.1247 · Cited by 1,090
The big picture on nanomedicine: the state of investigational and approved nanomedicine products
Etheridge, M. L., Campbell, S. A., Erdman, A. G., Haynes, C. L., Wolf, S. M., & McCullough, J. (2013) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2012.05.013 · Cited by 1,088
Adriamycin: A New Anticancer Drug with Significant Clinical Activity
BLUM, R. H., & CARTER, S. K. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-2-249 · Cited by 1,057
Computationally Guided Photothermal Tumor Therapy Using Long-Circulating Gold Nanorod Antennas
von Maltzahn, G., Park, J.-H., Agrawal, A., Bandaru, N. K., Das, S. K., Sailor, M. J., & Bhatia, S. N. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4242 · Cited by 1,051
Von Hoff, D. D., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., Korn, R. L., Desai, N., Trieu, V., Iglesias, J. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5742 · Cited by 1,044
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Louvet, C., Labianca, R., Hammel, P., Lledo, G., Zampino, M. G., André, T., Zaniboni, A., Ducreux, M., Aitini, E., Taïeb, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.023 · Cited by 950
Haran, G., Cohen, R., Bar, L. K., & Barenholz, Y. (1993) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(93)90105-9 · Cited by 934
Dose Escalation Methods in Phase I Cancer Clinical Trials
Le Tourneau, C., Lee, J. J., & Siu, L. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp079 · Cited by 867
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
Wang, F., Wang, Y.-C., Dou, S., Xiong, M.-H., Sun, T.-M., & Wang, J. (2011) · ACS Nano · doi:10.1021/nn200007z · Cited by 813
Amphotericin B formulations: a comparative review of efficacy and toxicity
Hamill, R. J. (2013) · Drugs · doi:10.1007/s40265-013-0069-4 · Cited by 807
Yeh, M.-K., Chang, H.-I., & Cheng, M.-Y. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s26766 · Cited by 801
Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5848 · Cited by 756
In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy
Kim, S. C., Kim, D. W., Shim, Y. H., Bang, J. S., Oh, H. S., Kim, S. W., & Seo, M. H. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00275-9 · Cited by 734
Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine
Libutti, S. K., Paciotti, G. F., Byrnes, A. A., Alexander, H. R., Gannon, W. E., Walker, M., Seidel, G. D., Yuldasheva, N., & Tamarkin, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0978 · Cited by 710
Ibrahim, N. K., Desai, N. P., Legha, S. S., Soon‐Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A. Y., Hortobágyi, G. N., et al. (2002) · PubMed · Cited by 705
Jordan, A., Wust, P., Fählin, H., John, W., Hinz, A., & Felix, R. (1993) · International Journal of Hyperthermia · doi:10.3109/02656739309061478 · Cited by 694
Vasey, P. A., Kaye, S. B., Morrison, R. A., Twelves, C. J., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., et al. (1999) · PubMed · Cited by 689
Heinemann, V., Quietzsch, D., Gieseler, F., Gonnermann, M., Schönekäs, H., Rost, A., Neuhaus, H., Haag, C., Clemens, M., Heinrich, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1490 · Cited by 683
Prevention of Anthracycline-Induced Cardiotoxicity
Vejpongsa, P., & Yeh, E. T. H. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.06.1167 · Cited by 671
Green, M. R., Manikhas, G. M., Orlov, S., Afanasyev, B., Makhson, A. M., Bhar, P., & Hawkins, M. J. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl104 · Cited by 667
Northfelt, D. W., Dezube, B. J., Thommes, J. A., Miller, B. J., Fischl, M. A., Friedman-Kien, A., Kaplan, L. D., Du Mond, C., Mamelok, R. D., & Henry, D. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2445 · Cited by 649
Muggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.987 · Cited by 647
Orlowski, R. Z., Nagler, A., Sonneveld, P., Bladé, J., Hajek, R., Spencer, A., San Miguel, J., Robak, T., Dmoszynska, A., Horvath, N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5460 · Cited by 645
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623
Beating cancer in multiple ways using nanogold
Dreaden, E. C., Mackey, M. A., Huang, X., Kang, B., & El-Sayed, M. A. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00180e · Cited by 605
Pharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Development of the polymer micelle carrier system for doxorubicin
Nakanishi, T., Fukushima, S., Okamoto, K., Suzuki, M., Matsumura, Y., Yokoyama, M., Okano, T., Sakurai, Y., & Kataoka, K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00341-8 · Cited by 570
Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602479 · Cited by 565
The anthracyclines: will we ever find a better doxorubicin?
Weiss, R. B. (1992) · PubMed · Cited by 558
Emerging concepts in dendrimer‐based nanomedicine: from design principles to clinical applications
Kannan, R. M., Nance, E., Kannan, S., & Tomalia, D. A. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12280 · Cited by 542
Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9591-y · Cited by 541
Wingard, J. R., White, M. H., Anaissie, E., Raffalli, J., Goodman, J., Arrieta, A., & L Amph/ABLC Collaborative Study Group (2000) · Clinical Infectious Diseases · doi:10.1086/317451 · Cited by 527
Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., Winer, E., & TLC D‐99 Study Group (2002) · Cancer · doi:10.1002/cncr.10201 · Cited by 512
Paclitaxel-Functionalized Gold Nanoparticles
Gibson, J. D., Khanal, B. P., & Zubarev, E. R. (2007) · Journal of the American Chemical Society · doi:10.1021/ja075181k · Cited by 484
Silverman, J. A., & Deitcher, S. R. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2042-4 · Cited by 474
du Bois, A., Quinn, M., Thigpen, T., Vermorken, J., Avall-Lundqvist, E., Bookman, M., Bowtell, D., Brady, M., Casado, A., Cervantes, A., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi961 · Cited by 465
PEG conjugates in clinical development or use as anticancer agents: An overview
Pasut, G., & Veronese, F. M. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.02.010 · Cited by 457
Phospholipid spherules (liposomes) as a model for biological membranes
Sessa, G., & Weissmann, G. (1968) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43097-4 · Cited by 446
Cisplatin: a review of toxicities and therapeutic applications
Barabas, K., Milner, R., Lurie, D., & Adin, C. (2008) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2007.00142.x · Cited by 446
Liposomes for use in gene delivery
Balazs, D. A., & Godbey, W. (2011) · Journal of Drug Delivery · doi:10.1155/2011/326497 · Cited by 441
Prentice, H. G., Hann, I. M., Herbrecht, R., Aoun, M., Kvaloy, S., Catovsky, D., Pinkerton, C. R., Schey, S. A., Jacobs, F., Oakhill, A., et al. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.2473063.x · Cited by 439
Gill, P. S., Wernz, J., Scadden, D. T., Cohen, P., Mukwaya, G. M., von Roenn, J. H., Jacobs, M., Kempin, S., Silverberg, I., Gonzales, G., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2353 · Cited by 438
Polymer-drug conjugates: Recent development in clinical oncology
Li, C., & Wallace, S. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.009 · Cited by 436
Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin
Seymour, L. W., Ferry, D. R., Anderson, D., Hesslewood, S., Julyan, P. J., Poyner, R., Doran, J., Young, A., Burtles, S. S., & Kerr, D. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1668 · Cited by 435
Heinemann, V., Boeck, S., Hinke, A., Labianca, R., & Louvet, C. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-82 · Cited by 434
Uchino, H., Matsumura, Y., Negishi, T., Koizumi, F., Hayashi, T., Honda, T., Nishiyama, N., Kataoka, K., Naito, S., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602772 · Cited by 430
Gordon, A. N., Tonda, M., Sun, S., & Rackoff, W. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.07.011 · Cited by 422
A randomized controlled study of iron supplementation in patients treated with erythropoietin
Macdougall, I. C., Tucker, B., Thompson, J., Tomson, C. R. V., Baker, L. R. I., & Raine, A. E. G. (1996) · Kidney International · doi:10.1038/ki.1996.487 · Cited by 417
Gregoriadis, G. (1973) · FEBS Letters · doi:10.1016/0014-5793(73)80394-1 · Cited by 414
Polymer therapeutics-prospects for 21st century: The end of the beginning
Duncan, R., & Vicent, M. J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.012 · Cited by 412
Lopez-Berestein, G., Fainstein, V., Hopfer, R., Mehta, K., Sullivan, M. P., Keating, M., Rosenblum, M. G., Mehta, R., Luna, M., Hersh, E. M., et al. (1985) · Journal of Infectious Diseases · doi:10.1093/infdis/151.4.704 · Cited by 405
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Glantz, M. J., LaFollette, S., Jaeckle, K. A., Shapiro, W., Swinnen, L., Rozental, J. R., Phuphanich, S., Rogers, L. R., Gutheil, J. C., Batchelor, T., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3110 · Cited by 402
DRUG-CARRIER POTENTIAL OF LIPOSOMES IN CANCER CHEMOTHERAPY
Gregoriadis, G., Swain, C. P., Wills, E. J., & Tavill, A. S. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90682-5 · Cited by 401
Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer
Huggett, M. T., Jermyn, M., Gillams, A., Illing, R., Mosse, S., Novelli, M., Kent, E., Bown, S. G., Hasan, T., Pogue, B. W., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.95 · Cited by 396
Plummer, R., Wilson, R. H., Calvert, H., Boddy, A. V., Griffin, M., Sludden, J., Tilby, M. J., Eatock, M., Pearson, D. G., Ottley, C. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.6 · Cited by 390
Colucci, G., Giuliani, F., Gebbia, V., Biglietto, M., Rabitti, P., Uomo, G., Cigolari, S., Testa, A., Maiello, E., & Lopez, M. (2002) · PubMed · Cited by 384
Danson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601856 · Cited by 382
Johannsen, M., Gneveckow, U., Taymoorian, K., Thiesen, B., Waldöfner, N., Scholz, R., Jung, K., Jordan, A., Wust, P., & Loening, S. A. (2007) · International Journal of Hyperthermia · doi:10.1080/02656730601175479 · Cited by 382
Nanoscale Radiotherapy with Hafnium Oxide Nanoparticles
Maggiorella, L., Barouch, G., Devaux, C., Pottier, A., Deutsch, E., Bourhis, J., Borghi, E., & Levy, L. (2012) · Future Oncology · doi:10.2217/fon.12.96 · Cited by 373
Hiscock, C., & ISDALE, I. C. (1964) · PubMed · Cited by 370
Stewart, S., Jablonowski, H., Goebel, F. D., Arasteh, K., Spittle, M., Rios, A., Aboulafia, D., Galleshaw, J., & Dezube, B. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.683 · Cited by 358
Tardi, P., Johnstone, S., Harasym, N., Xie, S., Harasym, T., Zisman, N., Harvie, P., Bermudes, D., & Mayer, L. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.06.028 · Cited by 356
Kim, D.-W., Kim, S.-Y., Kim, H.-K., Kim, S.-W., Shin, S. W., Kim, J. S., Park, K., Lee, M. Y., & Heo, D. S. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm374 · Cited by 356
Gorfine, S. R., Onel, E., Patou, G., & Krivokapic, Z. V. (2011) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e318232d4c1 · Cited by 352
Polymer–drug conjugates: Origins, progress to date and future directions
Kopeček, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.014 · Cited by 347
Meers, P., Neville, M., Malinin, V., Scotto, A. W., Sardaryan, G., Kurumunda, R., Mackinson, C., James, G., Fisher, S., & Perkins, W. R. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn059 · Cited by 345
Li, C., Yu, D. F., Newman, R. A., Cabral, F., Stephens, L. C., Hunter, N. R., Milas, L., & Wallace, S. (1998) · PubMed · Cited by 340
Lancet, J. E., Cortes, J. E., Hogge, D. E., Tallman, M. S., Kovacsovics, T. J., Damon, L. E., Komrokji, R., Solomon, S. R., Kolitz, J. E., Cooper, M., et al. (2014) · Blood · doi:10.1182/blood-2013-12-540971 · Cited by 339
(1999) · PubMed · Cited by 337
Gordon, A. N., Granai, C. O., Rose, P. G., Hainsworth, J., Lopez, A., Weissman, C., Rosales, R., & Sharpington, T. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3093 · Cited by 336
Mignani, S., El Kazzouli, S., Bousmina, M., & Majoral, J.-P. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.01.001 · Cited by 335
Bowden, R., Chandrasekar, P., White, M. H., Li, X., Pietrelli, L., Gurwith, M., van Burik, J., Laverdiere, M., Safrin, S., & Wingard, J. R. (2002) · Clinical Infectious Diseases · doi:10.1086/341401 · Cited by 335
Enzyme entrapment in liposomes
Gregoriadis, G., Leathwood, P. D., & Ryman, B. E. (1971) · FEBS Letters · doi:10.1016/0014-5793(71)80109-6 · Cited by 331
Effects of Magnetic Fluid Hyperthermia (MFH) on C3H mammary carcinoma in vivo
Jordan, A., Scholz, R., Wust, P., Fähling, H., Krause, J., Wlodarczyk, W., Sander, B., Vogl, T., & Felix, R. (1997) · International Journal of Hyperthermia · doi:10.3109/02656739709023559 · Cited by 325
McCarthy, T. D., Karellas, P., Henderson, S. A., Giannis, M., O'Keefe, D. F., Heery, G., Paull, J. R. A., Matthews, B. R., & Holan, G. (2005) · Molecular Pharmaceutics · doi:10.1021/mp050023q · Cited by 314
Poste, G. H., Bucana, C. D., Raz, A., Bugelski, P. J., Kirsh, R. L., & Fidler, I. J. (1982) · PubMed · Cited by 309
Colucci, G., Giuliani, F., Gebbia, V., Biglietto, M., Rabitti, P., Uomo, G., Cigolari, S., Testa, A., Maiello, E., & Lopez, M. (2002) · Cancer · doi:10.1002/cncr.10323 · Cited by 307
Seymour (2009) · International Journal of Oncology · doi:10.3892/ijo_00000293 · Cited by 304
Valle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K., & Ranson, M. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9399-1 · Cited by 303
Ranson, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.13.1074 · Cited by 303
White, M. H., Bowden, R. A., Sandler, E. S., Graham, M. L., Noskin, G. A., Wingard, J. R., Goldman, M., van Burik, J., McCabe, A., Lin, J., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/514672 · Cited by 303
Lopez-Berestein, G., Mehta, R., Hopfer, R. L., Mills, K., Kasi, L., Mehta, K., Fainstein, V., Luna, M., Hersh, E. M., & Juliano, R. (1983) · Journal of Infectious Diseases · doi:10.1093/infdis/147.5.939 · Cited by 303
Meyerhoff, A. (1999) · Clinical Infectious Diseases · doi:10.1086/515085 · Cited by 295
Eleven years of Inflexal® V—a virosomal adjuvanted influenza vaccine
Herzog, C., Hartmann, K., Künzi, V., Kürsteiner, O., Mischler, R., Lazar, H., & Glück, R. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.05.029 · Cited by 292
Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases
Gregoriadis, G., & Ryman, B. E. (1971) · Biochemical Journal · doi:10.1042/bj1240058p · Cited by 286
Nyman, D. W., Campbell, K. J., Hersh, E., Long, K., Richardson, K., Trieu, V., Desai, N., Hawkins, M. J., & Von Hoff, D. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.6148 · Cited by 286
Cytarabine and neurologic toxicity.
Baker, W. J., Royer, G. L., & Weiss, R. B. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.4.679 · Cited by 285
Intravenous Iron Dextran in Clinical Medicine
Hamstra, R. D. (1980) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1980.03300430028018 · Cited by 280
The safety of intravenous iron dextran in hemodialysis patients
Fishbane, S., Ungureanu, V.-D., Maesaka, J. K., Kaupke, C. J., Lim, V., & Wish, J. (1996) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(96)90463-1 · Cited by 272
Winer, E. P., Berry, D. A., Woolf, S., Duggan, D., Kornblith, A., Harris, L. N., Michaelson, R. A., Kirshner, J. A., Fleming, G. F., Perry, M. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.048 · Cited by 270
Ibrahim, N. K., Samuels, B., Page, R., Doval, D., Patel, K. M., Rao, S. C., Nair, M. K., Bhar, P., Desai, N., & Hortobagyi, G. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.013 · Cited by 267
Ferumoxytol for Treating Iron Deficiency Anemia in CKD
Spinowitz, B. S., Kausz, A. T., Baptista, J., Noble, S. D., Sothinathan, R., Bernardo, M. V., Brenner, L., & Pereira, B. J. G. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007101156 · Cited by 262
Bellin, M. F., Roy, C., Kinkel, K., Thoumas, D., Zaim, S., Vanel, D., Tuchmann, C., Richard, F., Jacqmin, D., Delcourt, A., et al. (1998) · Radiology · doi:10.1148/radiology.207.3.9609907 · Cited by 261
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial
Meunier, F., Prentice, H. G., & Ringden, O. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.83 · Cited by 247
Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.
Gill, P. S., Espina, B. M., Muggia, F., Cabriales, S., Tulpule, A., Esplin, J. A., Liebman, H. A., Forssen, E., Ross, M. E., & Levine, A. M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.4.996 · Cited by 242
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
Yuan, R., Kay, A., Berg, W. J., & Lebwohl, D. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-45 · Cited by 240
Toxic effect of tumor necrosis factor on tumor vasculature in mice.
Watanabe, N., Niitsu, Y., Umeno, H., Kuriyama, H., Neda, H., Yamauchi, N., Maeda, M., & Urushizaki, I. (1988) · PubMed · Cited by 237
Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors
Senzer, N., Nemunaitis, J., Nemunaitis, D., Bedell, C., Edelman, G., Barve, M., Nunan, R., Pirollo, K. F., Rait, A., & Chang, E. H. (2013) · Molecular Therapy · doi:10.1038/mt.2013.32 · Cited by 236
Epaxal®: a virosomal vaccine to prevent hepatitis A infection
Bovier, P. A. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.8.1141 · Cited by 233
Design of Multifunctional Gold Nanoparticles for In Vitro and In Vivo Gene Silencing
Conde, J., Ambrosone, A., Sanz, V., Hernandez, Y., Marchesano, V., Tian, F., Child, H., Berry, C. C., Ibarra, M. R., Baptista, P. V., et al. (2012) · ACS Nano · doi:10.1021/nn3030223 · Cited by 232
Matsumura, Y. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.05.008 · Cited by 230
Weiss, G. J., Chao, J., Neidhart, J. D., Ramanathan, R. K., Bassett, D., Neidhart, J. A., Choi, C. H. J., Chow, W., Chung, V., Forman, S. J., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9921-8 · Cited by 230
Batrakova, E., Dorodnych, T., Klinskii, E., Kliushnenkova, E., Shemchukova, O., Goncharova, O., Arjakov, S., Alakhov, V., & Kabanov, A. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.587 · Cited by 228
Combating the Drug Resistance of Cisplatin Using a Platinum Prodrug Based Delivery System
Min, Y., Mao, C., Chen, S., Ma, G., Wang, J., & Liu, Y. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201562 · Cited by 222
Self-citationPhase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection
Clancy, J. P., Dupont, L., Konstan, M. W., Billings, J., Fustik, S., Goss, C. H., Lymp, J., Minic, P., Quittner, A. L., Rubenstein, R. C., et al. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202230 · Cited by 222
Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models
Schluep, T., Hwang, J., Cheng, J., Heidel, J. D., Bartlett, D. W., Hollister, B., & Davis, M. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1566 · Cited by 222
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.
Lopez-Berestein, G., Bodey, G. P., Frankel, L. S., & Mehta, K. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.2.310 · Cited by 216
Keller, A. M., Mennel, R. G., Georgoulias, V. A., Nabholtz, J.-M., Erazo, A., Lluch, A., Vogel, C. L., Kaufmann, M., von Minckwitz, G., Henderson, I. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.157 · Cited by 214
A review of the current status of siRNA nanomedicines in the treatment of cancer
Resnier, P., Montier, T., Mathieu, V., Benoit, J.-P., & Passirani, C. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.04.060 · Cited by 210
Hortobagyi, G. N., Ueno, N. T., Xia, W., Zhang, S., Wolf, J. K., Putnam, J. B., Weiden, P. L., Willey, J. S., Carey, M., Branham, D. L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3422 · Cited by 208
Liposomal doxorubicin (Doxil): An effective new treatment for Kaposi's sarcoma in AIDS
James, N. D., Coker, R. J., Tomlinson, D., Harris, J. R. W., Gompels, M., Pinching, A. J., & Stewart, J. S. W. (1994) · Clinical Oncology · doi:10.1016/s0936-6555(05)80269-9 · Cited by 205
Langer, C. J., O’Byrne, K. J., Socinski, M. A., Mikhailov, S. M., Leśniewski-Kmak, K., Smakal, M., Ciuleanu, T. E., Orlov, S. V., Dediu, M., Heigener, D., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181753b4b · Cited by 202
Ivy, S. P., Siu, L. L., Garrett-Mayer, E., & Rubinstein, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1961 · Cited by 199
HPMA copolymers with pH-controlled release of doxorubicin
Ulbrich, K., Etrych, T., Chytil, P., Jelı́nková, M., & Řı́hová, B. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00348-6 · Cited by 198
Thill, M., Kurylcio, A., Welter, R., van Haasteren, V., Grosse, B., Berclaz, G., Polkowski, W., & Hauser, N. (2014) · The Breast · doi:10.1016/j.breast.2014.01.004 · Cited by 197
O'Brien, S., Schiller, G., Lister, J., Damon, L., Goldberg, S., Aulitzky, W., Ben-Yehuda, D., Stock, W., Coutre, S., Douer, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2309 · Cited by 196
Phase I clinical evaluation of a new iron oxide MR contrast agent
McLachlan, S. J., Morris, M. R., Lucas, M. A., Fisco, R. A., Eakins, M. N., Fowler, D. R., Scheetz, R. B., & Olukotun, A. Y. (1994) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1880040313 · Cited by 194
Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells
Mehta, R., Lopez-Berestein, G., Hopfer, R., Mills, K., & Juliano, R. L. (1984) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(84)90135-4 · Cited by 192
Resnik, D. B., & Tinkle, S. S. (2007) · Nanomedicine · doi:10.2217/17435889.2.3.345 · Cited by 192
Preparation of multivesicular liposomes
Kim, S., Turker, M. S., Chi, E. Y., Sela, S., & Martin, G. M. (1983) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(83)90504-7 · Cited by 190
Ferumoxytol as an Intravenous Iron Replacement Therapy in Hemodialysis Patients
Provenzano, R., Schiller, B., Rao, M., Coyne, D., Brenner, L., & Pereira, B. J. G. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02840608 · Cited by 187
Biodistribution of TNF-α-Coated Gold Nanoparticles in An In Vivo Model System
Goel, R., Shah, N., Visaria, R., Paciotti, G. F., & Bischof, J. C. (2009) · Nanomedicine · doi:10.2217/nnm.09.21 · Cited by 186
Ahn, H. K., Jung, M., Sym, S. J., Shin, D. B., Kang, S. M., Kyung, S. Y., Park, J.-W., Jeong, S. H., & Cho, E. K. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2498-5 · Cited by 183
Hahn, P. F., Stark, D. D., Lewis, J. M., Saini, S., Elizondo, G., Weissleder, R., Fretz, C. J., & Ferrucci, J. T. (1990) · Radiology · doi:10.1148/radiology.175.3.2343116 · Cited by 181
Combating the Drug Resistance of Cisplatin Using a Platinum Prodrug Based Delivery System
Min, Y., Mao, C., Chen, S., Ma, G., Wang, J., & Liu, Y. (2012) · Angewandte Chemie · doi:10.1002/ange.201201562 · Cited by 181
Self-citationCortes, J. E., Goldberg, S. L., Feldman, E. J., Rizzeri, D. A., Hogge, D. E., Larson, M., Pigneux, A., Recher, C., Schiller, G., Warzocha, K., et al. (2015) · Cancer · doi:10.1002/cncr.28974 · Cited by 175
Price, C. F., Tyssen, D., Sonza, S., Davie, A., Evans, S., Lewis, G. R., Xia, S., Spelman, T., Hodsman, P., Moench, T. R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024095 · Cited by 173
Angst, M. S., & Drover, D. R. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645120-00002 · Cited by 173
Designing dendrimers for ocular drug delivery
Spataro, G., Malecaze, F., Turrin, C.-O., Soler, V., Duhayon, C., Elena, P.-P., Majoral, J.-P., & Caminade, A.-M. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.10.017 · Cited by 172
Paz-Ares, L., Ross, H., O'Brien, M., Riviere, A., Gatzemeier, U., Von Pawel, J., Kaukel, E., Freitag, L., Digel, W., Bischoff, H., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604372 · Cited by 171
From idea to market: the drug approval process.
Lipsky, M. S., & Sharp, L. K. (2001) · PubMed · Cited by 170
Suspected anaphylactic reaction to Cremophor EL.
Dye, D., & Watkins, J. (1980) · BMJ · doi:10.1136/bmj.280.6228.1353 · Cited by 169
Superparamagnetic Iron Oxide–enhanced MR Imaging of Head and Neck Lymph Nodes
Mack, M. G., Balzer, J. O., Straub, R., Eichler, K., & Vogl, T. J. (2002) · Radiology · doi:10.1148/radiol.2221010225 · Cited by 167
Chan, S. Y. T., Davidson, N. G. P., Juozaitytė, E., Erdkamp, F., Pluzanska, A., Azarnia, N., & Lee, L. W. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh393 · Cited by 167
Cirstea, D., Hideshima, T., Rodig, S., Santo, L., Pozzi, S., Vallet, S., Ikeda, H., Perrone, G., Gorgun, G., Patel, K., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0763 · Cited by 167
Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.
White, M. H., Anaissie, E. J., Kusne, S., Wingard, J. R., Hiemenz, J., Cantor, A. B., Gurwith, M., Mond, C. D., Mamelok, R. D., & Bowden, R. A. (1997) · PubMed · Cited by 166
Lim, W.-S., Tardi, P. G., Dos Santos, N., Xie, X., Fan, M., Liboiron, B. D., Huang, X., Harasym, T. O., Bermudes, D., & Mayer, L. D. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.01.015 · Cited by 164
Treatment of Non-small Cell Lung Cancer, Stage IIIB
Jett, J. R., Schild, S. E., Keith, R. L., & Kesler, K. A. (2007) · CHEST Journal · doi:10.1378/chest.07-1380 · Cited by 162
Jiang, Y.-H., Emau, P., Cairns, J. S., Flanary, L., Morton, W. R., McCarthy, T. D., & Tsai, C.-C. (2005) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2005.21.207 · Cited by 160
Ko, A. H., Tempero, M. A., Shan, Y.-S., Su, W.-C., Lin, Y.-L., Dito, E., Ong, A., Wang, Y.-W., Yeh, C. G., & Chen, L.-T. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.408 · Cited by 160
Seymour, L., Ivy, S. P., Sargent, D., Spriggs, D., Baker, L., Rubinstein, L., Ratain, M. J., Le Blanc, M., Stewart, D., Crowley, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3287 · Cited by 158
Functional reconstitution of influenza virus envelopes.
Stegmann, T., Morselt, H. W. M., Booy, F. P., van Breemen, J. F., Scherphof, G. L., & Wilschut, J. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02556.x · Cited by 158
Taxol: a history of pharmaceutical development and current pharmaceutical concerns.
Adams, J. D., Flora, K. P., Goldspiel, B. R., Wilson, J., Arbuck, S. G., & Finley, R. W. (1993) · PubMed · Cited by 157
A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin.
Rahman, A., Treat, J., Roh, J. K., Potkul, L., Alvord, W. G., Forst, D. A., & Woolley, P. V. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.6.1093 · Cited by 157
Markman, M., KENNEDY, A. W., Webster, K. D., Peterson, G., Kulp, B., & Belinson, J. L. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5921 · Cited by 155
Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101
Svenson, S., Wolfgang, M., Hwang, J., Ryan, J. L., & Eliasof, S. D. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.03.007 · Cited by 153
Hafnium oxide nanoparticles: toward an in vitropredictive biological effect?
Marill, J., Anesary, N. M., Zhang, P., Vivet, S., Borghi, E., Lévy, L., & Pottier, A. (2014) · Radiation Oncology · doi:10.1186/1748-717x-9-150 · Cited by 149
On the relative safety of parenteral iron formulations
Chertow, G. M., Mason, P. D., Vaage-Nilsen, O., & Ahlmén, J. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh185 · Cited by 149
Gambling, D. R., Hughes, T., Martin, G., Horton, W., & Manvelian, G. Z. (2005) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000145009.03574.78 · Cited by 148
Safety of Ferumoxytol in Patients With Anemia and CKD
Singh, A. K., Patel, T. V., Hertel, J., Bernardo, M. V., Kausz, A., & Brenner, L. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.08.001 · Cited by 147
Lim, W., Tan, E. H., Toh, C., Hee, S. W., Leong, S. S., Ang, P., Wong, N. S., & Chowbay, B. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp315 · Cited by 146
Rodriguez, M. A., Pytlík, R., Kozák, T., Chhanabhai, M., Gascoyne, R. D., Lu, B., Deitcher, S. R., & Winter, J. N. (2009) · Cancer · doi:10.1002/cncr.24359 · Cited by 145
Hamaguchi, T., Doi, T., Nakajima, T. E., Kato, K., Yamada, Y., Shimada, Y., Fuse, N., Ohtsu, A., Matsumoto, S.-I., Takanashi, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0387 · Cited by 145
Roy, V., LaPlant, B. R., Gross, G. G., Bane, C. L., & Palmieri, F. M. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn661 · Cited by 145
Physicochemical properties of ferumoxytol, a new intravenous iron preparation
Balakrishnan, V. S., Rao, M., Kausz, A. T., Brenner, L., Pereira, B. J. G., Frigo, T. B., & Lewis, J. M. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02130.x · Cited by 144
Gabizón, A., Chisin, R., Amselem, S., Druckmann, S., Cohen, R., Goren, D., Fromer, I. R., Peretz, T., Sulkes, A., & Barenholz, Y. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.476 · Cited by 144
Venuganti, V. V. K., & Perumal, O. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21603 · Cited by 142
Schluep, T., Cheng, J., Khin, K. T., & Davis, M. E. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0091-7 · Cited by 142
Ko, Y., Canil, C., Mukherjee, S. D., Winquist, E., Elser, C., Eisen, A. F., Reaume, M. N., Zhang, L., & Sridhar, S. S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70162-1 · Cited by 138
Application of liposomal technologies for delivery of platinum analogs in oncology
Wang, A. Z., Lin, W., Liu, D., & He, C. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s38354 · Cited by 130
Self-citationSystemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study
Gabizón, A., Peretz, T., Sulkes, A., Amselem, S., Ben‐Yosef, R., Ben-Baruch, N. E., Catane, R., Biran, S., & Barenholz, Y. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90350-7 · Cited by 130
Polyanions — A Lost Chance in the Fight against HIV and other Virus Diseases?
Lüscher-Mattii, M. (2000) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020001100401 · Cited by 130
Seront, E., Rottey, S., Sautois, B. R., Kerger, J. N., D'Hondt, L. A., Verschaeve, V., Canon, J. L., Dopchie, C., Vandenbulcke, J., Whenham, N., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds057 · Cited by 129
From “Banghasomes” to liposomes: A memoir of Alec Bangham, 1921–2010
Deamer, D. W. (2010) · The FASEB Journal · doi:10.1096/fj.10-0503 · Cited by 129
Cited by
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Reactive Oxygen Species (ROS)-Based Nanomedicine
Yang, B., Chen, Y., & Shi, J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00626 · Cited by 2,443
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
Zhou, Z., Song, J., Nie, L., & Chen, X. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00271d · Cited by 2,098
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Diverse Applications of Nanomedicine
Pelaz, B., Alexiou, C., Alvarez-Puebla, R. A., Alves, F., Andrews, A. M., Ashraf, S., Balogh, L. P., Ballerini, L., Bestetti, A., Brendel, C., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b06040 · Cited by 1,350
Metadata
- Authors
- Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-06-19
- Volume
- 115
- Issue
- 19
- Pages
- 11147-11190
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2297044638
- Cited by
- 772
- References
- 325
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.